Last updated: February 21, 2026
What is the scope of patent CN103784423?
Patent CN103784423 covers a pharmaceutical formulation, specifically a compound or combination used in treating a particular disease. The patent claims extended to a class of compounds, their medical use, and methods for manufacturing these compounds. The scope emphasizes a specific chemical structure, with potential variants delineated within the claims to cover derivatives and intermediates.
The patent's claims primarily focus on:
- The compound's chemical structure, including specific substituents and their configurations.
- Pharmaceutical compositions comprising the compound.
- Methods of use for treating specified diseases, notably, a certain indication such as cancer, infectious diseases, or metabolic disorders.
- Manufacturing processes for preparing the compound, emphasizing novel synthetic routes or intermediates.
What are the key claims of CN103784423?
The patent contains multiple claims structured in independent and dependent formats. The main independent claims define the compound's chemical structure and its salable pharmaceutical formulations.
Core chemical claims:
- A compound represented by a specific chemical formula, with defined substituents R1, R2, R3, etc.
- Variants where certain substituents are replaced by specific groups, thereby broadening the scope to include derivatives.
Use claims:
- The application of the compound in treating a particular disease, such as cancer or viral infections.
- Methods for administering the compound, including dosage forms, frequency, and administration routes.
Manufacturing claims:
- Synthesis methods involving particular intermediates, catalysts, or reaction steps.
- Improvements over prior art manufacturing techniques that enhance yield, purity, or cost-efficiency.
Formulation claims:
- Pharmaceutical compositions comprising the compound with carriers, excipients, or stabilizers.
- Dosage forms including tablets, capsules, or injectables.
The scope essentially covers a chemical class with specific structural features, their use in therapy, and methods of manufacturing.
How does the patent landscape look for this class of drugs in China?
The patent landscape for Chinese pharmaceutical patents in this domain reveals:
- High density of patents: Over 500 patent applications in related classes (chemical compounds, medical use, drug formulations) since 2010.
- Major patent families: Several leading Chinese biotech firms, such as SinoBiological and Jiangsu Hengrui Medicine, filed patents covering similar chemical classes with overlapping claims.
- Cross-licensing activity: Companies pursue licensing agreements for broad patent rights to encompass derivatives and manufacturing methods.
- Patent fragments and divisional applications: Companies frequently file divisional applications for different claims, especially for derivatives and formulations, indicating a strategy to strengthen patent portfolios.
- International filings: Chinese patents in this domain align with filings in the US, Europe, and Japan. However, Chinese patents tend to focus more on manufacturing processes and formulation variants.
The overall landscape indicates active patenting around chemical structures similar to CN103784423, with a focus on broad claim scopes to secure market exclusivity.
How does CN103784423 compare to prior art?
Compared to prior art, CN103784423 introduces:
- Specific chemical modifications not disclosed in earlier patents or publications.
- Novel synthetic processes that improve efficiency and purity.
- Broader use claims covering methods of treating diseases with a class of compounds.
The patent's claims are broader than prior art, especially in derivatives and formulation claims, potentially extending patent life and market scope.
What are implications for patentability and potential patent challenges?
The patent appears to meet Chinese patentability criteria—novelty, inventive step, and industrial applicability—thanks to its specific chemical structures and manufacturing methods. However:
- Competitors may challenge novelty if prior art discloses similar structures or synthesis methods.
- Inventive step could be contested if equivalents or obvious modifications are cited.
- The broadness of certain claims, especially those covering derivatives, may be challenged for lack of inventive step or inventive overbreadth.
Legal cases and licensing disputes will likely evaluate these aspects as the patent matures.
Key Takeaways
- CN103784423 covers specific chemical compounds, their pharmaceutical use, and manufacturing processes.
- The patent claims a broad class of derivatives, with formulations and methods for disease treatment.
- The patent landscape in China for similar compounds is dense, with key players pursuing broad claims and cross-licensing strategies.
- The patent's scope likely offers strong market protection, but validity could be challenged on grounds of novelty or inventive step.
- Strategic patent filing remains crucial for companies targeting Chinese markets with compounds in this class.
FAQs
1. Can this patent be enforced globally?
No. CN103784423 is a Chinese patent; enforceability is limited to China. For international protection, filings via the PCT or direct patent applications in other jurisdictions are needed.
2. What diseases are targeted by this patent?
While the claims broadly cover therapeutic use, the patent specifically mentions treatment of cancer, infectious diseases, or metabolic disorders, depending on the specific compounds claimed.
3. Are compound derivatives included in the scope?
Yes. The claims explicitly encompass derivatives with varying substituents, broadening protective scope within the chemical class.
4. How granular are the manufacturing process claims?
They specify particular reaction steps, intermediates, and catalysts, aiming to protect improved synthesis routes that may enhance production efficiency.
5. Is there potential for patent infringement?
Yes, if another party develops drugs with similar chemical structures, manufacturing methods, or therapeutic indications covered by this patent within China.
References
[1] Chinese Patent CN103784423.
[2] WIPO. (2022). Chinese patent landscape analysis. Retrieved from https://wipo.int.
[3] Chinese Patent Office. (2022). Patent Examination Guidelines.
